Hemophilia A is characterized by deficiency in factor VIII clotting activity that results in
prolonged oozing after injuries, tooth extractions, or surgery, and delayed or recurrent …

Hemophilia A is an X-linked genetic disorder caused by mutations in the F8 gene, which
encodes the blood coagulation factor VIII. Almost half of all severe hemophilia A cases result …

Background Black patients with hemophilia A (factor VIII deficiency) are twice as likely as
white patients to produce inhibitors against factor VIII proteins given as replacement therapy …

Hemophilia A and B are rare, X-linked bleeding disorders. My Life, Our Future (MLOF) is a
collaborative project established to genotype and study hemophilia. Patients were enrolled …

Both genetic and treatment‐related risk factors contribute to the development of inhibitors in
haemophilia. An inhibitor surveillance system piloted at 12 US sites has the goal of …

Background: Inversions of F8‐intron 22 (Inv22) and F8‐intron 1 (Inv1) are responsible for 45–
50% of severe hemophilia A cases. Objective: In order to improve the molecular diagnosis of …

The factor VIII gene (F8) intron 22 inversion (Inv22) is a paradigmatic duplicon-mediated
rearrangement, found in about one half of patients with severe hemophilia A worldwide. The …

Direct detection of F8 and F9 sequence variants in maternal plasma of hemophilia carriers
has been demonstrated by microfluidics digital PCR. Noninvasive prenatal assessment of …

One‐third of the UK haemophilia A population was screened to establish a national
database of mutations and pedigrees and advance knowledge of the disease. The following …

Background: Twenty‐five percent of new anti‐factor VIII (FVIII) antibodies (inhibitors) that
complicate hemophilia A occur in those with mild and moderate disease. Although intensive …